UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 429

Sortiert nach

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Clinical cancer research, 2021-11, Vol.27 (21), p.5818-5827

2021

Volltextzugriff (PDF)

Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression

Breast (Edinburgh), 2022-08, Vol.64, p.100-111

2022

Volltextzugriff (PDF)

The entanglements which make instruments musical: Rediscovering sociality

Journal of new music research, 2021-03, Vol.50 (2), p.133-146

Waters, Simon

2021

Volltextzugriff (PDF)

Networks of Innovation, Connection and Continuity in Woodwind Designa nd Manufacture in London between 1760 and 1840

The Galpin Society journal, 2020-03, Vol.73, p.10-247

Waters, Simon

2020

Volltextzugriff (PDF)

Co-designing a new approach to delivering integrated services to chronically ill patients within existing funding constraints – Victoria’s HealthLinks trial

International journal of integrated care, 2019-08, Vol.19 (4), p.322

2019

Volltextzugriff (PDF)

Contribution Towards an Ethics of Listening: An Improvising Musician’s Perspective

Critical studies in improvisation, 2018-03, Vol.12 (1)

Waters, Simon

2018

Volltextzugriff (PDF)

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

The lancet oncology, 2020-03, Vol.21 (3), p.345-357

2020

Volltextzugriff (PDF)

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

The lancet oncology, 2018-03, Vol.19 (3), p.323-336

2018

Volltextzugriff (PDF)

Engendering Hope: A Person-Centred Reflection on Technology and Gender

Contemporary music review, 2016-01, Vol.35 (1), p.61-70

Waters, Simon

2016

Volltextzugriff (PDF)

Tullis Rennie's Muscle Memory: Listening to the Act of Listening

Contemporary music review, 2015-01, Vol.34 (1), p.22-32

Waters, Simon

2015

Volltextzugriff (PDF)

Touching at a Distance: Resistance, Tactility, Proxemics and the Development of a Hybrid Virtual/Physical Performance System

Contemporary music review, 2013-06, Vol.32 (2-3), p.119-134

Waters, Simon

2013

Volltextzugriff (PDF)

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

The Lancet (British edition), 2019-06, Vol.393 (10191), p.2599-2612

2019

Volltextzugriff (PDF)

Abstract P1-18-06: Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer, followed by T-DM1 after progression

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-06

2022

Volltextzugriff (PDF)

The AusPSIs: the Australian Version of the Agency of Healthcare Research and Quality Patient Safety Indicators

Australian health review, 2009-05, Vol.33 (2), p.334-350

2009

Volltextzugriff (PDF)

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Clinical cancer research, 2024-02, Vol.30 (4), p.895

2024

Volltextzugriff (PDF)

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1005-1005

2022

Volltextzugriff (PDF)

Single Domain Intracellular Antibodies from Diverse Libraries: EMPHASIZING DUAL FUNCTIONS OF LMO2 PROTEIN INTERACTIONS USING A SINGLE VH DOMAIN

The Journal of biological chemistry, 2011-02, Vol.286 (5), p.3707-3716

2011

Volltextzugriff (PDF)

Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS1111-TPS1111

2023

Volltextzugriff (PDF)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

Breast cancer research and treatment, 2023-05, Vol.199 (1), p.35-46

2023

Volltextzugriff (PDF)

Abstract P3-11-09: ARISTACAT - Ar omatase i nhibition plus minus s araca t inib as a dvanced breast ca ncer t herapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-11-09

2020

Volltextzugriff (PDF)

1 – 25 von 429

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(362)
Mit Volltextzugriff
(382)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression

The entanglements which make instruments musical: Rediscovering sociality

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer

Networks of Innovation, Connection and Continuity in Woodwind Designa nd Manufacture in London between 1760 and 1840

Co-designing a new approach to delivering integrated services to chronically ill patients within existing funding constraints – Victoria’s HealthLinks trial

Contribution Towards an Ethics of Listening: An Improvising Musician’s Perspective

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group

Engendering Hope: A Person-Centred Reflection on Technology and Gender

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Tullis Rennie's Muscle Memory: Listening to the Act of Listening

Touching at a Distance: Resistance, Tactility, Proxemics and the Development of a Hybrid Virtual/Physical Performance System

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Abstract P1-18-06: Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer, followed by T-DM1 after progression

The AusPSIs: the Australian Version of the Agency of Healthcare Research and Quality Patient Safety Indicators

Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis

Single Domain Intracellular Antibodies from Diverse Libraries: EMPHASIZING DUAL FUNCTIONS OF LMO2 PROTEIN INTERACTIONS USING A SINGLE VH DOMAIN

Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)

Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

Abstract P3-11-09: ARISTACAT - Ar omatase i nhibition plus minus s araca t inib as a dvanced breast ca ncer t herapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

Suchergebnisse filtern